How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,243 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2014 Clinical Trials

122. Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic – Induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MScPhm, ACPR, FCSHP Sabrina Boodhan BScPhm, ACPR Lillian Sung MD, PhD Carol Portwine MD, FRCPC, PhD Richard Hain MD Patricia McCarthy RN, (EC), MSc(A) Mark (...) and the expert consensus of the POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Group, the following classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients is recommended: Recommendation: The single antineoplastic agents provided in Table 1 have high, moderate, low or minimal emetogenic potential in children. Table 1: Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Given

2010 SickKids Supportive Care Guidelines

123. Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea

Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea Fidaxomicin in C. difficile Diarrhea - Wiki Journal Club Fidaxomicin in C. difficile Diarrhea From Wiki Journal Club (Redirected from ) Jump to: , Louie TJ, et al. "Fidaxomicin versus Vancomycin for Clostridium difficile Infection". The New England Journal of Medicine . 2011. 365(5):422-431. • • Contents Clinical Question In patients with Clostridium difficile -associated diarrhea, is treatment (...) with fidaxomicin non-inferior to vancomycin in terms of clinical cure? Bottom Line Fidaxomicin was noninferior to vancomycin in achieving rates of clinical cure among patients with Clostridium difficile -associated diarrhea and resulted in fewer recurrent infections. Major Points Clostridium difficile -associated diarrhea (CDAD) is a major adverse effect of antibiotic usage and its incidence is on the rise, particularly among hospitalized patients receiving broad-spectrum antibiotics. While the trial (2007

2011 Wiki Journal Club

124. Zarxio (filgrastim-sndz) - medical review

Zarxio (filgrastim-sndz) - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125553Orig1s000 MEDICAL REVIEW(S) Page 1 Secondary (Team Leader) Review Date February 3, 2015 From Albert Deisseroth, MD, PhD Subject Secondary Review BLA Number 125553 Applicant Sandoz Date of Submission May 8, 2014 PDUFA Goal Date March 8, 2015 Proprietary Name Zarxio Dosage Regimen 300 mcg/0.5 mL PFS, 480 mcg/0.8 mL PFS Approved Indications Patients with cancer receiving myelosuppressive (...) chemotherapy; Patients with AML receiving induction or consolidation chemotherapy; Patients with cancer receiving bone marrow transplant; Patients undergoing peripheral blood progenitor cell collection; Patients with severe chronic neutropenia. Recommendation: Approval of EP2006 as a biosimilar to US-licensed Neupogen for all 5 indications for which US-licensed Neupogen is currently licensed Material Reviewed/Consulted Reviewer/Author Medical Officer Review Donna Przepiorka, MD, PhD Clinical Pharmacology

2015 FDA - Drug Approval Package

125. Diarrhea in HIV

) These images are a random sampling from a Bing search on the term "Diarrhea in HIV." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Diarrhea About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Diarrhea in HIV Diarrhea in HIV Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea in HIV Diarrhea in HIV Aka: Diarrhea in HIV

2015 FP Notebook

126. Acute Diarrhea

, Diarrhea , Acute Infectious Diarrhea , Infectious Diarrhea , Bacterial Diarrhea From Related Chapters II. Definition Inflammation of the gastrointestinal tract ( e and ) Typical presentation is followed by Diarrhea Most typically secondary to Can also be caused by with ingestion of preformed toxin Diarrhea Frequent liquid stools Adults: >200 g/day of stool (at least 3 s daily) Children: >20 g/kg/day of stool Timing Acute Diarrhea: Duration <2 weeks : Duration >4 weeks III. Epidemiology Foodbourne (...) es (30-40% of episodes) (90% of non- l diarhea) and s (20-30% of episodes) Inflammatory Diarrhea from and s (most common ) Shiga-toxin producing (e.g. :H7, ) Causes 30% of infectious bloody Diarrhea Non-inflammatory Diarrhea from and s Bacillus cereus VII. Risk Factors See for systemic medical condition causes of Diarrhea See Recent travel to endemic area See Travel to a developing area is associated with a 25% chance of developing Diarrhea Those with Diarrhea in a developing area have an 80

2015 FP Notebook

127. Antibiotic Associated Diarrhea

Diarrhea Antibiotic Associated Diarrhea Aka: Antibiotic Associated Diarrhea , Diarrhea Secondary to Antibiotic Use , Antibiotic-Associated Diarrhea From Related Chapters II. Precautions Antibiotics in the emergency department frequently cause IV antibiotics: 26% of cases Oral antibiotics: 12% of cases , and antibiotic combinations were highest risk for Reconsider whether antibiotics are indicated and if so, if IV route is needed Oral bioavailability of most antibiotics is excellent Single dose IV (...) antibiotics prior to home oral antibiotics is rarely indicated References Arora and Menchine in Herbert (2015) EM:Rap 15(1): 11 III. Causes: Bacterial Overgrowth Syndromes secondary to antibiotics oxytoca Responds to stopping antibiotics (and possibly to stopping s) IV. Prevention: Probiotics Efficacy (NNT): 13 Treating 13 patients prevents one case of Antibiotic Associated Diarrhea Live-culture yogurt reduces due to antibiotics Lactobacillus acidophilus Lactobacillus bulgaricus thermophilus Other

2015 FP Notebook

128. Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01597505 Recruitment Status : Completed First Posted : May 14, 2012 Results First Posted : February 28, 2018 Last Update Posted

2012 Clinical Trials

129. Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

(mean) Secondary Outcome Measures : Evaluate the Clinical Outcome by Assessment of Clinical Response. [ Time Frame: Day 10 ] Positive clinical response defined as resolution of diarrhea Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. [ Time Frame: 28 days post-treatment ] Positive clinical response without recurrence through the follow-up period Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important (...) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2012 Clinical Trials

130. A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. Secondary Outcome Measures : Number of Clinical Failure Events up to Day 40 [ Time Frame: Up to 30 days after EOT (up to Day 40) ] The total number of clinical failure events, which included treatment failure, CDAD recurrence, death, or being lost to follow-up, occurring during each time period was determined in each arm. Adjusted (...) A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2012 Clinical Trials

131. Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea

to include fever and gross blood in stool, as well as report of no impact on activity AND, no treatment failure events to include the following: Recurrence of diarrheal illness meeting case definition of TD occurring within 72 hours after clinical cure Worsening of, or failure to improve after 24 hours of therapy Illness continuing after 72 hours Secondary Outcome Measures : Time to Last Unformed Stool [ Time Frame: 24, 48, 72 hours ] Calculated as the time from taking the first dose of study medication (...) , Naval Medical Research Center ClinicalTrials.gov Identifier: Other Study ID Numbers: IDCRP-065 First Posted: June 13, 2012 Last Update Posted: November 28, 2016 Last Verified: November 2016 Keywords provided by Mark Riddle, CDR, MC, USN, Naval Medical Research Center: diarrhea travelers' diarrhea watery diarrhea enteric illness dysentery gastrointestinal Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Fever Dysentery Signs and Symptoms, Digestive Signs and Symptoms Body

2012 Clinical Trials

132. Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants

Centro Pediatrico Albina Ptino More Information Go to Layout table for additonal information Responsible Party: Giuseppe Grandy, Medical Chief of Nutrition Center, Centro Pediatrico Albina de Patino ClinicalTrials.gov Identifier: Other Study ID Numbers: protzinc2012 First Posted: April 5, 2012 Last Update Posted: May 7, 2013 Last Verified: May 2013 Keywords provided by Giuseppe Grandy, Centro Pediatrico Albina de Patino: Acute Diarrhea Zinc Children Additional relevant MeSH terms: Layout table (...) Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Use

2012 Clinical Trials

133. Diarrhea and Oral Polio Vaccine Immunity

for poliovirus type 1 or 3 Seroconversion: proportion of children who change from seronegative to seropositive to types 1 or 3, four weeks after receipt of bOPV. Boost (increase in titer): seropositives at baseline who increase at least 4-fold in antibody titer four weeks after receipt of bOPV. Secondary Outcome Measures : Frequencies of enteric infections isolated in stool among infants with diarrhea vs. infants without diarrhea [ Time Frame: Date of enrollment ] One stool sample will be collected from each (...) Diarrhea and Oral Polio Vaccine Immunity Diarrhea and Bivalent Oral Polio Vaccine Immunity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diarrhea and Bivalent Oral Polio Vaccine Immunity The safety

2012 Clinical Trials

134. Efficacy of Racecadotril in Acute Watery Diarrhea in Children

Efficacy of Racecadotril in Acute Watery Diarrhea in Children Efficacy of Racecadotril in Acute Watery Diarrhea in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Racecadotril in Acute (...) Watery Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01577043 Recruitment Status : Completed First Posted : April 13, 2012 Last Update Posted : April 13, 2012 Sponsor: Centro Pediatrico Albina de Patino Information provided by (Responsible Party): Giuseppe Grandy, Centro

2012 Clinical Trials

135. Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

by C. difficile toxin assay. Wald 95% Confidence Intervals (CI) are presented. Secondary Outcome Measures : Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 60 Days Post-treatment. [ Time Frame: Up to 60 days post-treatment ] CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool (...) Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2012 Clinical Trials

136. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01736423 Recruitment Status : Completed First Posted : November 29, 2012 Last Update Posted : October 12, 2015 Sponsor

2012 Clinical Trials

137. Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

days from Day 1 chemotherapy Placebo Comparator: Placebo Drug: Placebo 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy Outcome Measures Go to Primary Outcome Measures : Number of Patients experiencing Diarrhea [ Time Frame: Day 1 to Day 14 ] Severity of Diarrhea will be classified according to the NCI-CTCAE. Secondary Outcome Measures : Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated [ Time Frame: Day 1 to Day 32 (...) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2012 Clinical Trials

138. Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea

Comparator: azithromycin azithromycin 500mg Drug: azithromycin azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg Other Name: zitromax Placebo Comparator: placebo placebo 500mg Drug: Placebo Outcome Measures Go to Primary Outcome Measures : Duration of diarrhea in days [ Time Frame: up to 10 days ] Secondary Outcome Measures : number of stools/day [ Time Frame: one day ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) prolongation. Patients treated with other active drugs that prolong the QT interval such as: antiarrhythmics of classes IA and III, cisapride and terfenadine. Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia. Patients with clinically relevant bradycardia, arrhythmia or severe heart failure. Inflammatory bowel diseases Chronic diarrhea of known cause. Dementia. Serious illness less than 21 days from the planned entry into the study. Patients treated with medications that have

2012 Clinical Trials

139. Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea

Bowel Syndrome (IBS) Patients With Diarrhea (IBS-D) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01667627 Recruitment Status : Completed First Posted : August 17, 2012 Last Update Posted : May 24, 2018 Sponsor: Tel-Aviv Sourasky Medical Center Information provided by (Responsible Party): Tel-Aviv (...) : Roy Dekel, MD Tel Aviv Medical Center More Information Go to Layout table for additonal information Responsible Party: Tel-Aviv Sourasky Medical Center ClinicalTrials.gov Identifier: Other Study ID Numbers: TASMC-11-RD-0491-CTIL First Posted: August 17, 2012 Last Update Posted: May 24, 2018 Last Verified: May 2018 Keywords provided by Tel-Aviv Sourasky Medical Center: IBS Probiotic hs-CRP Cholinergic status Micro-inflammation Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea

2012 Clinical Trials

140. Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children

. Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01968408 Recruitment Status : Completed First Posted : October 24, 2013 Last Update Posted : June 18, 2015 Sponsor: Medical University of Warsaw Information provided by (Responsible (...) Party): Hanna Szajewska, Medical University of Warsaw Study Details Study Description Go to Brief Summary: AIM: To determine the efficacy of Lactobacillus reuteri DSM 17938 at a dose of 10(9) CFU for the prevention of nosocomial diarrhea. TRIAL DESIGN: Double-blind, placebo controlled RCT. INTERVENTION: L reuteri DSM 17938 in a daily dose of 10(9) CFU. PRIMARY OUTCOME: Nosocomial diarrhoea (3 or more loose or watery stools in a 24 h that will occur more than 72 h after admission). Condition

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>